Iridium Reiterates FY24 Service Revenue Growth Outlook - Update

RTTNews | 33 hari yang lalu
Iridium Reiterates FY24 Service Revenue Growth Outlook - Update

(RTTNews) - While reporting financial results for the first quarter on Thursday, Iridium Communications Inc. (IRDM) reiterated its total service revenue growth guidance for the full-year 2024.

For fiscal 2024, the company still projects service revenue growth of 4 to 6 percent, compared to the $584.5 million reported in 2023.

On average, seven analysts polled by Thomson Reuters expect the company to report revenues of $799.30 million for the year.

The Board of Directors plans to increase the quarterly dividend by 5.8 percent to $0.14 per share starting with the second quarter 2024 dividend.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

read more
Iridium Boosts FY22 Service Revenue Growth Outlook - Update

Iridium Boosts FY22 Service Revenue Growth Outlook - Update

While reporting financial results for the third quarter on Thursday, Iridium Communications Inc. (IRDM) raised its total service revenue growth guidance for the full-year 2022, based upon the momentum seen across all commercial business lines.
RTTNews | 579 hari yang lalu
Iridium Boosts FY22 Revenue Outlook - Update

Iridium Boosts FY22 Revenue Outlook - Update

While reporting financial results for the second quarter on Tuesday, Iridium Communications Inc. (IRDM) raised its total service revenue growth guidance for the full-year 2022, based upon the momentum still seen from its extensive global ecosystem of business partners.
RTTNews | 665 hari yang lalu
European Shares Decline On US Rate Concerns

European Shares Decline On US Rate Concerns

European stocks edged lower on Tuesday following cautious comments from Federal Reserve officials on inflation and the interest rate outlook.
RTTNews | 5j 40min yang lalu
Sanofi, OpenAI To Build AI Software To Boost Drug Development

Sanofi, OpenAI To Build AI Software To Boost Drug Development

French drug major Sanofi is teaming with artificial intelligence or AI startup OpenAI, the developer of highly popular generative AI chatbot ChatGPT, as well as Formation Bio, an AI and tech-driven drug developer, to build AI-powered software to accelerate drug development and bring new medicines more efficiently.
RTTNews | 5j 46min yang lalu